AT280356B
(de)
|
1968-03-06 |
1970-04-10 |
Telefonbau & Normalzeit Gmbh |
Schaltungsanordnung zur Steuerung des zur Zwischenspeicherung des Zeitwertes eines Signales verwendeten Kondensators eines Demodulators einer Zeitmultiplexanlage
|
US4376110A
(en)
|
1980-08-04 |
1983-03-08 |
Hybritech, Incorporated |
Immunometric assays using monoclonal antibodies
|
US4554101A
(en)
|
1981-01-09 |
1985-11-19 |
New York Blood Center, Inc. |
Identification and preparation of epitopes on antigens and allergens on the basis of hydrophilicity
|
CH660375A5
(it)
*
|
1983-02-08 |
1987-04-15 |
Sclavo Spa |
Procedimento per la produzione di proteine correlate alla tossina difterica.
|
US4708871A
(en)
|
1983-03-08 |
1987-11-24 |
Commonwealth Serum Laboratories Commission |
Antigenically active amino acid sequences
|
US4816567A
(en)
|
1983-04-08 |
1989-03-28 |
Genentech, Inc. |
Recombinant immunoglobin preparations
|
US4650764A
(en)
|
1983-04-12 |
1987-03-17 |
Wisconsin Alumni Research Foundation |
Helper cell
|
US4668829A
(en)
*
|
1984-07-18 |
1987-05-26 |
University Patents, Inc. |
Ferroelectric smectic liquid crystals
|
JPS6147500A
(ja)
|
1984-08-15 |
1986-03-07 |
Res Dev Corp Of Japan |
キメラモノクロ−ナル抗体及びその製造法
|
EP0173494A3
(en)
|
1984-08-27 |
1987-11-25 |
The Board Of Trustees Of The Leland Stanford Junior University |
Chimeric receptors by dna splicing and expression
|
GB8422238D0
(en)
|
1984-09-03 |
1984-10-10 |
Neuberger M S |
Chimeric proteins
|
GB8424757D0
(en)
|
1984-10-01 |
1984-11-07 |
Pasteur Institut |
Retroviral vector
|
SE8405493D0
(sv)
*
|
1984-11-01 |
1984-11-01 |
Bror Morein |
Immunogent komplex samt sett for framstellning derav och anvendning derav som immunstimulerande medel
|
FR2573436B1
(fr)
|
1984-11-20 |
1989-02-17 |
Pasteur Institut |
Adn recombinant comportant une sequence nucleotidique codant pour un polypeptide determine sous le controle d'un promoteur d'adenovirus, vecteurs contenant cet adn recombinant, cellules eucaryotes transformees par cet adn recombinant, produits d'excretion de ces cellules transformees et leurs applications, notamment a la constitution de vaccins
|
JPS61134325A
(ja)
|
1984-12-04 |
1986-06-21 |
Teijin Ltd |
ハイブリツド抗体遺伝子の発現方法
|
US4797368A
(en)
*
|
1985-03-15 |
1989-01-10 |
The United States Of America As Represented By The Department Of Health And Human Services |
Adeno-associated virus as eukaryotic expression vector
|
US4666829A
(en)
|
1985-05-15 |
1987-05-19 |
University Of California |
Polypeptide marker for Alzheimer's disease and its use for diagnosis
|
EP0232262A4
(en)
|
1985-08-15 |
1989-09-19 |
Stauffer Chemical Co |
MICROORGANISM PRODUCING TRYPTOPHANE.
|
US5078996A
(en)
*
|
1985-08-16 |
1992-01-07 |
Immunex Corporation |
Activation of macrophage tumoricidal activity by granulocyte-macrophage colony stimulating factor
|
US5139941A
(en)
|
1985-10-31 |
1992-08-18 |
University Of Florida Research Foundation, Inc. |
AAV transduction vectors
|
EP0247091B1
(en)
|
1985-11-01 |
1993-09-29 |
Xoma Corporation |
Modular assembly of antibody genes, antibodies prepared thereby and use
|
US4861719A
(en)
|
1986-04-25 |
1989-08-29 |
Fred Hutchinson Cancer Research Center |
DNA constructs for retrovirus packaging cell lines
|
US5514581A
(en)
|
1986-11-04 |
1996-05-07 |
Protein Polymer Technologies, Inc. |
Functional recombinantly prepared synthetic protein polymer
|
US4980289A
(en)
|
1987-04-27 |
1990-12-25 |
Wisconsin Alumni Research Foundation |
Promoter deficient retroviral vector
|
US5057540A
(en)
*
|
1987-05-29 |
1991-10-15 |
Cambridge Biotech Corporation |
Saponin adjuvant
|
RU2023448C1
(ru)
|
1987-07-30 |
1994-11-30 |
Сентро Насьональ Де Биопрепарадос |
Способ получения вакцины против различных патогенных серотипов менингита нейссера группы в
|
JPH01144977A
(ja)
|
1987-11-30 |
1989-06-07 |
Agency Of Ind Science & Technol |
新規組換えプラスミドpTPGIF2
|
AU3069189A
(en)
|
1988-02-05 |
1989-08-25 |
Trustees Of Columbia University In The City Of New York, The |
Retroviral packaging cell lines and processes of using same
|
US4912094B1
(en)
*
|
1988-06-29 |
1994-02-15 |
Ribi Immunochem Research Inc. |
Modified lipopolysaccharides and process of preparation
|
EP0432216A1
(en)
|
1988-09-01 |
1991-06-19 |
Whitehead Institute For Biomedical Research |
Recombinant retroviruses with amphotropic and ecotropic host ranges
|
US7118757B1
(en)
|
1988-12-19 |
2006-10-10 |
Wyeth Holdings Corporation |
Meningococcal class 1 outer-membrane protein vaccine
|
US5124263A
(en)
*
|
1989-01-12 |
1992-06-23 |
Wisconsin Alumni Research Foundation |
Recombination resistant retroviral helper cell and products produced thereby
|
CA2047681C
(en)
|
1989-03-09 |
2000-02-01 |
Bruce A. Green |
Vaccines for nontypable haemophilus influenzae
|
US5354844A
(en)
|
1989-03-16 |
1994-10-11 |
Boehringer Ingelheim International Gmbh |
Protein-polycation conjugates
|
US5703055A
(en)
|
1989-03-21 |
1997-12-30 |
Wisconsin Alumni Research Foundation |
Generation of antibodies through lipid mediated DNA delivery
|
HU212924B
(en)
|
1989-05-25 |
1996-12-30 |
Chiron Corp |
Adjuvant formulation comprising a submicron oil droplet emulsion
|
US5399346A
(en)
|
1989-06-14 |
1995-03-21 |
The United States Of America As Represented By The Department Of Health And Human Services |
Gene therapy
|
US5585362A
(en)
|
1989-08-22 |
1996-12-17 |
The Regents Of The University Of Michigan |
Adenovirus vectors for gene therapy
|
CA2039921A1
(en)
|
1990-04-16 |
1991-10-17 |
Xandra O. Breakefield |
Transfer and expression of gene sequences into central nervous system cells using herpes simplex virus mutants with deletions in genes for viral replication
|
US5264618A
(en)
*
|
1990-04-19 |
1993-11-23 |
Vical, Inc. |
Cationic lipids for intracellular delivery of biologically active molecules
|
WO1991018088A1
(en)
|
1990-05-23 |
1991-11-28 |
The United States Of America, Represented By The Secretary, United States Department Of Commerce |
Adeno-associated virus (aav)-based eucaryotic vectors
|
IE912559A1
(en)
|
1990-07-19 |
1992-01-29 |
Merck & Co Inc |
The class ii protein of the outer membrane of neisseria¹meningitidis, and vaccines containing same
|
JPH0453645U
(da)
*
|
1990-09-12 |
1992-05-07 |
|
|
BR9106879A
(pt)
|
1990-09-25 |
1993-07-20 |
Cantab Pharma Res |
Virus mutuante nao retroviral,uso do mesmo,vacina e processo de manufaturar umvirus mutante
|
US5173414A
(en)
|
1990-10-30 |
1992-12-22 |
Applied Immune Sciences, Inc. |
Production of recombinant adeno-associated virus vectors
|
IL101715A
(en)
|
1991-05-02 |
2005-06-19 |
Amgen Inc |
Recombinant dna-derived cholera toxin subunit analogs
|
WO1993007897A1
(en)
|
1991-10-21 |
1993-04-29 |
Medimmune, Inc. |
Bacterial expression vectors containing dna encoding secretion signals of lipoproteins
|
US5252479A
(en)
|
1991-11-08 |
1993-10-12 |
Research Corporation Technologies, Inc. |
Safe vector for gene therapy
|
IT1253009B
(it)
|
1991-12-31 |
1995-07-10 |
Sclavo Ricerca S R L |
Mutanti immunogenici detossificati della tossina colerica e della tossina lt, loro preparazione ed uso per la preparazione di vaccini
|
WO1993015115A1
(en)
|
1992-01-24 |
1993-08-05 |
Cornell Research Foundation, Inc. |
E. coli dna polymerase iii holoenzyme and subunits
|
EP0673431A1
(en)
|
1992-12-03 |
1995-09-27 |
Genzyme Corporation |
Gene therapy for cystic fibrosis
|
DE69434079T2
(de)
*
|
1993-03-05 |
2005-02-24 |
Wyeth Holdings Corp. |
Plasmid zur Herstellung von CRM-Protein und Diphtherie-Toxin
|
WO1994021807A2
(en)
|
1993-03-19 |
1994-09-29 |
Cantab Pharmaceuticals Research Limited |
Defective mutant non-retroviral virus (e.g. hsv) as vaccine
|
DE69423383T2
(de)
|
1993-05-13 |
2000-08-24 |
American Cyanamid Co |
Herstellung und Verwendungen von LOS-verminderten Aussenmembran-Proteinen von Gram-negativen Kokken
|
FR2705361B1
(fr)
|
1993-05-18 |
1995-08-04 |
Centre Nat Rech Scient |
Vecteurs viraux et utilisation en thérapie génique.
|
FR2705686B1
(fr)
|
1993-05-28 |
1995-08-18 |
Transgene Sa |
Nouveaux adénovirus défectifs et lignées de complémentation correspondantes.
|
ES2310924T3
(es)
|
1993-07-13 |
2009-01-16 |
Centelion |
Vectores adenovirales defectivos y utilizacion en terapia genica.
|
US5439808A
(en)
*
|
1993-07-23 |
1995-08-08 |
North American Vaccine, Inc. |
Method for the high level expression, purification and refolding of the outer membrane group B porin proteins from Neisseria meningitidis
|
AU7477394A
(en)
|
1993-07-30 |
1995-03-27 |
University Of Medicine And Dentistry Of New Jersey |
Efficient gene transfer into primary lymphocytes
|
FR2708622B1
(fr)
|
1993-08-02 |
1997-04-18 |
Raymond Hamers |
Vecteur recombinant contenant une séquence d'un gène de lipoprotéine de structure pour l'expression de séquences de nucléotides.
|
US5550213A
(en)
|
1993-12-27 |
1996-08-27 |
Rutgers, The State University Of New Jersey |
Inhibitors of urokinase plasminogen activator
|
FR2714830B1
(fr)
|
1994-01-10 |
1996-03-22 |
Rhone Poulenc Rorer Sa |
Composition contenant des acides nucléiques, préparation et utilisations.
|
FR2715847B1
(fr)
|
1994-02-08 |
1996-04-12 |
Rhone Poulenc Rorer Sa |
Composition contenant des acides nucléiques, préparation et utilisations.
|
FI98045C
(fi)
|
1994-02-21 |
1997-04-10 |
Arto Remes |
Laite inkontinenssihoitoa varten
|
FR2716459B1
(fr)
|
1994-02-22 |
1996-05-10 |
Univ Paris Curie |
Système hôte-vecteur utilisable en thérapie génique.
|
WO1995026411A2
(en)
|
1994-03-25 |
1995-10-05 |
The Uab Research Foundation |
Composition and methods for creating syngeneic recombinant virus-producing cells
|
US5739118A
(en)
|
1994-04-01 |
1998-04-14 |
Apollon, Inc. |
Compositions and methods for delivery of genetic material
|
JPH10501963A
(ja)
|
1994-04-15 |
1998-02-24 |
ターゲテッド ジェネティクス コーポレイション |
遺伝子送達融合タンパク質
|
US5571515A
(en)
*
|
1994-04-18 |
1996-11-05 |
The Wistar Institute Of Anatomy & Biology |
Compositions and methods for use of IL-12 as an adjuvant
|
WO1995029662A2
(en)
*
|
1994-04-20 |
1995-11-09 |
U.S. Department Of The Army |
Vaccine against gram-negative bacterial infections
|
US6207646B1
(en)
|
1994-07-15 |
2001-03-27 |
University Of Iowa Research Foundation |
Immunostimulatory nucleic acid molecules
|
US5565204A
(en)
*
|
1994-08-24 |
1996-10-15 |
American Cyanamid Company |
Pneumococcal polysaccharide-recombinant pneumolysin conjugate vaccines for immunization against pneumococcal infections
|
US5837533A
(en)
|
1994-09-28 |
1998-11-17 |
American Home Products Corporation |
Complexes comprising a nucleic acid bound to a cationic polyamine having an endosome disruption agent
|
GB9422096D0
(en)
|
1994-11-02 |
1994-12-21 |
Biocine Spa |
Combined meningitis vaccine
|
FR2727679B1
(fr)
|
1994-12-05 |
1997-01-03 |
Rhone Poulenc Rorer Sa |
Nouveaux agents de transfection et leurs applications pharmaceutiques
|
BE1008978A5
(fr)
|
1994-12-27 |
1996-10-01 |
Solvay |
Adjuvants pour vaccins.
|
IL116816A
(en)
|
1995-01-20 |
2003-05-29 |
Rhone Poulenc Rorer Sa |
Cell for the production of a defective recombinant adenovirus or an adeno-associated virus and the various uses thereof
|
FR2730637B1
(fr)
|
1995-02-17 |
1997-03-28 |
Rhone Poulenc Rorer Sa |
Composition pharmaceutique contenant des acides nucleiques, et ses utilisations
|
IL117483A
(en)
|
1995-03-17 |
2008-03-20 |
Bernard Brodeur |
MENINGITIDIS NEISSERIA shell protein is resistant to proteinase K.
|
WO1996039036A1
(en)
|
1995-06-05 |
1996-12-12 |
The University Of Alabama At Birmingham Research Foundation |
Composition and methods for creating syngeneic recombinant virus-producing cells
|
IL118578A
(en)
*
|
1995-06-07 |
2006-12-31 |
Connaught Lab |
Hybrid nucleic acid molecule for expression of lipoproteins
|
FR2741358B1
(fr)
|
1995-11-17 |
1998-01-02 |
Centre Nat Rech Scient |
Production de vecteurs retroviraux par l'intermediaire de vecteurs viraux a base de virus a adn
|
CU22559A1
(es)
*
|
1996-01-17 |
1999-05-03 |
Ct Ingenieria Genetica Biotech |
Sistema de expresión de antígenos heterologos en e. coli como proteínas de fusión
|
US6355255B1
(en)
*
|
1998-12-07 |
2002-03-12 |
Regents Of The University Of Minnesota |
Streptococcal C5a peptidase vaccine
|
US5846547A
(en)
|
1996-01-22 |
1998-12-08 |
Regents Of The University Of Minnesota |
Streptococcal C5a peptidase vaccine
|
CA2264585C
(en)
|
1996-08-27 |
2005-06-14 |
Chiron Corporation |
Monoclonal antibodies that define unique meningococcal b epitopes and their use in the preparation of vaccine compositions
|
DK0939647T4
(da)
|
1996-08-27 |
2006-10-23 |
Novartis Vaccines & Diagnostic |
Neisseria Meningitidis-serogruppe B-glycokonjugat og fremgangsmåde til anvendelse deraf
|
GB9622159D0
(en)
|
1996-10-24 |
1996-12-18 |
Solvay Sociutu Anonyme |
Polyanionic polymers as adjuvants for mucosal immunization
|
AU5426098A
(en)
|
1996-10-24 |
1998-05-15 |
Emory University |
Invasion associated genes from (neisseria meningitidis) serogroup
|
GB9622660D0
(en)
|
1996-10-31 |
1997-01-08 |
Biocine Spa |
Immunogenic detoxified mutant toxin
|
US6113918A
(en)
*
|
1997-05-08 |
2000-09-05 |
Ribi Immunochem Research, Inc. |
Aminoalkyl glucosamine phosphate compounds and their use as adjuvants and immunoeffectors
|
DE19723095C2
(de)
*
|
1997-06-02 |
2001-08-23 |
Siemens Ag |
Bildrekonstruktionsverfahren für einen Computertomographen
|
DE69826124T3
(de)
|
1997-06-30 |
2007-10-11 |
Institut Gustave Roussy |
Verabreichung der nukleinsäure in den quergestreiften muskel
|
JP2002515816A
(ja)
|
1997-06-30 |
2002-05-28 |
アバンテイス・フアルマ・エス・アー |
in vivo組織に核酸ベクターを最適に電気導入する装置
|
BR9810372A
(pt)
|
1997-06-30 |
2000-09-05 |
Rhone Poulenc Rorer Sa |
Processo de transferência de ácido nucléico para o interior de células de organismos eucarióticos pluricelulares in vivo, composição, ácido nucléico e campo elétrico, e, produto de combinação
|
CA2297072A1
(en)
*
|
1997-07-17 |
1999-01-28 |
North American Vaccine, Inc. |
Immunogenic conjugates comprising a group b meningococcal porin and an h. influenzae polysaccharide
|
JPH1144977A
(ja)
|
1997-07-25 |
1999-02-16 |
Copyer Co Ltd |
画像形成装置
|
AU9120898A
(en)
|
1997-08-27 |
1999-03-16 |
Chiron Corporation |
Molecular mimetics of meningococcal b epitopes
|
JP2001514269A
(ja)
*
|
1997-08-29 |
2001-09-11 |
ザ ダウ ケミカル カンパニー |
均質な、充填剤含有高分子複合体
|
AU9363798A
(en)
|
1997-11-06 |
1999-05-31 |
Chiron S.P.A. |
Neisserial antigens
|
TWI239847B
(en)
|
1997-12-02 |
2005-09-21 |
Elan Pharm Inc |
N-terminal fragment of Abeta peptide and an adjuvant for preventing and treating amyloidogenic disease
|
EP2210945B1
(en)
|
1998-01-14 |
2013-06-26 |
Novartis Vaccines and Diagnostics S.r.l. |
Neisseria meningitidis antigens
|
CA2319404C
(en)
*
|
1998-02-03 |
2014-01-07 |
Edwin W. Ades |
Recombinant lipidated psaa protein, methods of preparation and use
|
GB9806456D0
(en)
|
1998-03-25 |
1998-05-27 |
Smithkline Beecham Biolog |
Vaccine composition
|
GB9808734D0
(en)
|
1998-04-23 |
1998-06-24 |
Smithkline Beecham Biolog |
Novel compounds
|
GB9808932D0
(en)
|
1998-04-27 |
1998-06-24 |
Chiron Spa |
Polyepitope carrier protein
|
AU761780B2
(en)
*
|
1998-05-01 |
2003-06-12 |
Glaxosmithkline Biologicals Sa |
Neisseria meningitidis antigens and compositions
|
DK1079857T3
(da)
|
1998-05-29 |
2007-01-29 |
Novartis Vaccines & Diagnostic |
Meningitidis B/C-kombinationsvacciner
|
AU1199900A
(en)
|
1998-09-30 |
2000-04-17 |
Walter Reed Army Institute Of Research |
Use of purified invaplex from gram negative bacteria as a vaccine
|
BR9914160A
(pt)
|
1998-09-30 |
2001-06-26 |
American Cyanamid Co |
Composição antigênica, método para aumentar a capacidade de uma composição antigênica que contenha um antìgeno selecionado de uma bactéria, vìrus, fungo ou parasita patogênicos, do haemophilus influenzae, do helicobacter pylori, do vìrus sincicial respiratório, do rotavìrus, e, do vìrus simples do herpes para evocar a resposta imune de um hospedeiro vertebrado, plasmìdeo, célula hospedeira, método para produzir uma holotoxina do cólera mutante imunogênica, e, uso de uma quantidade auxiliar eficaz de uma holotoxina do cólera mutante
|
AU1202200A
(en)
|
1998-10-09 |
2000-05-01 |
Chiron Corporation |
Neisseria genomic sequences and methods of their use
|
US6660843B1
(en)
*
|
1998-10-23 |
2003-12-09 |
Amgen Inc. |
Modified peptides as therapeutic agents
|
US6281337B1
(en)
|
1998-11-12 |
2001-08-28 |
Schering Corporation |
Methods for conversion of protein isoforms
|
CA2359486A1
(en)
|
1999-01-15 |
2000-07-20 |
Smithkline Beecham Biologicals S.A. |
Neisseria meningitidis polypeptide basb052
|
AU2292800A
(en)
|
1999-01-22 |
2000-08-07 |
Smithkline Beecham Biologicals (Sa) |
Neisseria meningitidis antigenic polypeptides, corresponding polynucleotides andprotective antibodies
|
GB9902084D0
(en)
*
|
1999-01-29 |
1999-03-24 |
Smithkline Beecham Biolog |
Novel compounds
|
PT1150712E
(pt)
|
1999-02-05 |
2008-12-22 |
Merck & Co Inc |
Formulações para a vacina do vírus do papiloma humano
|
JP4812942B2
(ja)
|
1999-02-26 |
2011-11-09 |
ノバルティス ヴァクシンズ アンド ダイアグノスティクス エスアールエル |
CGモチーフを含むオリゴヌクレオチドを用いるNeisseria抗原殺菌活性の増強
|
US6245568B1
(en)
|
1999-03-26 |
2001-06-12 |
Merck & Co., Inc. |
Human papilloma virus vaccine with disassembled and reassembled virus-like particles
|
US7115730B1
(en)
|
1999-04-27 |
2006-10-03 |
Chiron Srl |
Immunogenic detoxified mutant E. coli LT-A-toxin
|
US7368261B1
(en)
|
1999-04-30 |
2008-05-06 |
Novartis Vaccines And Diagnostics Srl |
Conserved Neisserial antigens
|
EP1605061A1
(en)
|
1999-04-30 |
2005-12-14 |
Chiron Corporation |
Neisseria genomic sequences and methods of their use
|
ES2563677T3
(es)
*
|
1999-05-19 |
2016-03-15 |
Glaxosmithkline Biologicals Sa |
Composiciones de combinaciones de Neisseria
|
GB9911683D0
(en)
|
1999-05-19 |
1999-07-21 |
Chiron Spa |
Antigenic peptides
|
GB9916529D0
(en)
|
1999-07-14 |
1999-09-15 |
Chiron Spa |
Antigenic peptides
|
GB9918319D0
(en)
*
|
1999-08-03 |
1999-10-06 |
Smithkline Beecham Biolog |
Vaccine composition
|
US7384640B1
(en)
|
1999-09-30 |
2008-06-10 |
Wyeth Holdings Corporation |
Mutant cholera holotoxin as an adjuvant
|
ES2559317T3
(es)
|
1999-10-29 |
2016-02-11 |
Glaxosmithkline Biologicals Sa |
Péptidos antigénicos de Neisseria
|
GB9928196D0
(en)
*
|
1999-11-29 |
2000-01-26 |
Chiron Spa |
Combinations of B, C and other antigens
|
JP4840956B2
(ja)
|
1999-11-29 |
2011-12-21 |
ノバルティス ヴァクシンズ アンド ダイアグノスティクス エスアールエル |
85kDaのナイセリア抗原
|
DE60039450D1
(de)
|
1999-12-02 |
2008-08-21 |
Novartis Vaccines & Diagnostic |
Zusammensetzungen und methoden zur stabilisierung von biologischen molekülen nach lyophilisierung
|
DE60142772D1
(de)
*
|
2000-01-17 |
2010-09-23 |
Novartis Vaccines & Diagnostic |
Membranvesikel (omv) impfstoff, der n. meningitidis serogruppe b membranproteine enthält
|
NZ521396A
(en)
|
2000-02-28 |
2004-06-25 |
Chiron S |
Fusion proteins comprising two or more Neisseria polypeptides
|
TR200302015T4
(tr)
|
2000-06-08 |
2004-01-21 |
Intercell Biomedizinische Forschungs-Und Entwicklungs Ag |
İmüno-uyarıcı oligodeoksinükleotitler
|
AT410635B
(de)
|
2000-10-18 |
2003-06-25 |
Cistem Biotechnologies Gmbh |
Vakzin-zusammensetzung
|
SI21352A
(sl)
|
2001-01-23 |
2004-06-30 |
Aventis Pasteur |
Multivalentno meningokokno cepivo iz konjugata polisaharida-proteina
|
GB0103424D0
(en)
*
|
2001-02-12 |
2001-03-28 |
Chiron Spa |
Gonococcus proteins
|
WO2002079246A2
(en)
|
2001-03-30 |
2002-10-10 |
Geneprot, Inc. |
Human arginine-rich protein-related compositions
|
US6942802B2
(en)
|
2001-04-13 |
2005-09-13 |
Wyeth Holdings Corporation |
Removal of bacterial endotoxin in a protein solution by immobilized metal affinity chromatography
|
JP2004529643A
(ja)
|
2001-04-17 |
2004-09-30 |
カイロン コーポレイション |
機能活性抗体を誘発する髄膜炎菌性bエピトープの分子模倣物
|
JP2005508143A
(ja)
|
2001-06-07 |
2005-03-31 |
ワイス・ホールデイングス・コーポレーシヨン |
アジュバントとしてのコレラホロトキシンの突然変異形
|
DE60234695D1
(de)
|
2001-06-07 |
2010-01-21 |
Univ Colorado |
Mutantenformen von cholera holotoxin als adjuvans
|
GB0115176D0
(en)
|
2001-06-20 |
2001-08-15 |
Chiron Spa |
Capular polysaccharide solubilisation and combination vaccines
|
CN100350972C
(zh)
|
2001-07-26 |
2007-11-28 |
启龙股份公司 |
含有铝佐剂和组氨酸的疫苗
|
GB0121591D0
(en)
|
2001-09-06 |
2001-10-24 |
Chiron Spa |
Hybrid and tandem expression of neisserial proteins
|
CA2460546A1
(en)
*
|
2001-09-14 |
2003-03-27 |
Invitrogen Corporation |
Dna polymerases and mutants thereof
|
MX339524B
(es)
|
2001-10-11 |
2016-05-30 |
Wyeth Corp |
Composiciones inmunogenicas novedosas para la prevencion y tratamiento de enfermedad meningococica.
|
GB0129007D0
(en)
|
2001-12-04 |
2002-01-23 |
Chiron Spa |
Adjuvanted antigenic meningococcal compositions
|
ES2616180T3
(es)
|
2002-03-26 |
2017-06-09 |
Glaxosmithkline Biologicals Sa |
Sacáridos modificados con estabilidad mejorada en agua para su uso como medicamento
|
DE60328481D1
(de)
|
2002-05-14 |
2009-09-03 |
Novartis Vaccines & Diagnostic |
Schleimhautapplizierter impfstoff, der das adjuvanz chitosan und menigokokkenantigene enthält
|
AU2003239744B2
(en)
|
2002-05-14 |
2008-07-03 |
Novartis Vaccines And Diagnostics S.R.L. |
Mucosal combination vaccines for bacterial meningitis
|
GB0302218D0
(en)
|
2003-01-30 |
2003-03-05 |
Chiron Sri |
Vaccine formulation & Mucosal delivery
|
GB0220194D0
(en)
|
2002-08-30 |
2002-10-09 |
Chiron Spa |
Improved vesicles
|
GB0220198D0
(en)
|
2002-08-30 |
2002-10-09 |
Chiron Spa |
Modified saccharides,conjugates thereof and their manufacture
|
US7785608B2
(en)
*
|
2002-08-30 |
2010-08-31 |
Wyeth Holdings Corporation |
Immunogenic compositions for the prevention and treatment of meningococcal disease
|
EP2353608B1
(en)
|
2002-10-11 |
2019-12-18 |
Novartis Vaccines and Diagnostics S.r.l. |
Polypeptide-vaccines for broad protection against hypervirulent meningococcal lineages
|
EP1562982B1
(en)
|
2002-11-15 |
2010-05-05 |
Novartis Vaccines and Diagnostics S.r.l. |
Unexpected surface proteins in neisseria meningitidis
|
GB0227346D0
(en)
*
|
2002-11-22 |
2002-12-31 |
Chiron Spa |
741
|
US20070148729A1
(en)
|
2003-01-15 |
2007-06-28 |
Farley John E |
Methods for increasing neisseria protein expression and compositions thereof
|
ES2411080T3
(es)
|
2003-01-30 |
2013-07-04 |
Novartis Ag |
Vacunas inyectables contra múltiples serogrupos de meningococos
|
US20060251675A1
(en)
|
2003-03-17 |
2006-11-09 |
Michael Hagen |
Mutant cholera holotoxin as an adjuvant and an antigen carrier protein
|
MXPA05011110A
(es)
|
2003-04-16 |
2006-01-24 |
Wyeth Corp |
Composiciones inmunogenicas novedosas para la prevencion y tratamiento de un padecimiento originado por meningococos.
|
CA2528007C
(en)
|
2003-06-02 |
2012-03-27 |
Chiron Corporation |
Immunogenic compositions based on microparticles comprising adsorbed toxoid and a polysaccharide-containing antigen
|
WO2005000345A2
(en)
|
2003-06-23 |
2005-01-06 |
Aventis Pasteur, Inc. |
Immunization method against neisseria meningitidis serogroups a and c
|
GB0316560D0
(en)
|
2003-07-15 |
2003-08-20 |
Chiron Srl |
Vesicle filtration
|
PT1670506E
(pt)
|
2003-10-02 |
2013-01-28 |
Novartis Ag |
Vacinas líquidas para serogrupos meningocócicos múltiplos
|
GB0323103D0
(en)
|
2003-10-02 |
2003-11-05 |
Chiron Srl |
De-acetylated saccharides
|
CA2551896A1
(en)
|
2003-12-30 |
2005-07-21 |
Wyeth |
Formulations of hydrophobic proteins in an immunogenic composition having improved tolerability
|
GB0406013D0
(en)
|
2004-03-17 |
2004-04-21 |
Chiron Srl |
Analysis of saccharide vaccines without interference
|
GB0408978D0
(en)
|
2004-04-22 |
2004-05-26 |
Chiron Srl |
Meningococcal fermentation for preparing conjugate vaccines
|
GB0408977D0
(en)
|
2004-04-22 |
2004-05-26 |
Chiron Srl |
Immunising against meningococcal serogroup Y using proteins
|
GB0409745D0
(en)
|
2004-04-30 |
2004-06-09 |
Chiron Srl |
Compositions including unconjugated carrier proteins
|
PL1740217T3
(pl)
|
2004-04-30 |
2012-03-30 |
Novartis Ag |
Szczepienie koniugatem meningokokowym
|
GB0500787D0
(en)
|
2005-01-14 |
2005-02-23 |
Chiron Srl |
Integration of meningococcal conjugate vaccination
|
GB0410220D0
(en)
|
2004-05-07 |
2004-06-09 |
Kirkham Lea Ann |
Mutant pneumolysin proteins
|
GB0411387D0
(en)
|
2004-05-21 |
2004-06-23 |
Chiron Srl |
Analysis of saccharide length
|
GB0413868D0
(en)
|
2004-06-21 |
2004-07-21 |
Chiron Srl |
Dimensional anlaysis of saccharide conjugates
|
US7915218B2
(en)
|
2004-07-23 |
2011-03-29 |
Novartis Ag |
Polypeptides for oligomeric assembly of antigens
|
GB0419408D0
(en)
|
2004-09-01 |
2004-10-06 |
Chiron Srl |
741 chimeric polypeptides
|
GB0419846D0
(en)
|
2004-09-07 |
2004-10-13 |
Chiron Srl |
Vaccine adjuvants for saccharides
|
GB0424092D0
(en)
|
2004-10-29 |
2004-12-01 |
Chiron Srl |
Immunogenic bacterial vesicles with outer membrane proteins
|
GB0428394D0
(en)
|
2004-12-24 |
2005-02-02 |
Chiron Srl |
Saccharide conjugate vaccines
|
EP2682126B1
(en)
|
2005-01-27 |
2016-11-23 |
Children's Hospital & Research Center at Oakland |
GNA1870-based vesicle vaccines for broad spectrum protection against diseases caused by Neisseria meningitidis
|
WO2006096701A2
(en)
|
2005-03-07 |
2006-09-14 |
Id Biomedical Corporation Of Quebec C.O.B. As Glaxosmithkline Biologicals North America |
Pharmaceutical liposomal compositions
|
WO2006120576A2
(en)
|
2005-05-06 |
2006-11-16 |
Novartis Vaccines And Diagnostics Srl |
Immunogens for meningitidis-a vaccines
|
KR20130122810A
(ko)
|
2005-06-27 |
2013-11-08 |
글락소스미스클라인 바이오로지칼즈 에스.에이. |
백신 제조 방법
|
ES2443529T3
(es)
|
2005-09-01 |
2014-02-19 |
Novartis Vaccines And Diagnostics Gmbh |
Vacunación múltiple incluyendo meningococo del serogrupo C
|
ES2407683T3
(es)
|
2005-09-05 |
2013-06-13 |
Glaxosmithkline Biologicals S.A. |
Ensayo bactericida del suero para antisuero específico de N.
Meningitidis
|
GB0524066D0
(en)
|
2005-11-25 |
2006-01-04 |
Chiron Srl |
741 ii
|
AU2006327023A1
(en)
|
2005-12-23 |
2007-06-28 |
Glaxosmithkline Biologicals Sa |
Conjugate vaccines
|
PL2004225T3
(pl)
|
2006-03-22 |
2012-09-28 |
Novartis Ag |
Schematy immunizacji koniugatami meningokokowymi
|
TW200806315A
(en)
|
2006-04-26 |
2008-02-01 |
Wyeth Corp |
Novel formulations which stabilize and inhibit precipitation of immunogenic compositions
|
US20070253985A1
(en)
|
2006-04-26 |
2007-11-01 |
Wyeth |
Novel processes for coating container means which inhibit precipitation of polysaccharide-protein conjugate formulations
|
ES2337309T5
(es)
|
2006-06-12 |
2013-07-30 |
Glaxosmithkline Biologicals S.A. |
Vacuna
|
GB0612854D0
(en)
|
2006-06-28 |
2006-08-09 |
Novartis Ag |
Saccharide analysis
|
CN101479293A
(zh)
|
2006-06-29 |
2009-07-08 |
诺华有限公司 |
脑膜炎奈瑟球菌多肽
|
HUE048973T2
(hu)
|
2006-07-27 |
2020-09-28 |
Wyeth Llc |
Nagy sejtsûrûségû, rátáplálásos-szakaszos fermentáló eljárás rekombináns fehérje elõállítására
|
AR064642A1
(es)
|
2006-12-22 |
2009-04-15 |
Wyeth Corp |
Polinucleotido vector que lo comprende celula recombinante que comprende el vector polipeptido , anticuerpo , composicion que comprende el polinucleotido , vector , celula recombinante polipeptido o anticuerpo , uso de la composicion y metodo para preparar la composicion misma y preparar una composi
|
GB0700562D0
(en)
|
2007-01-11 |
2007-02-21 |
Novartis Vaccines & Diagnostic |
Modified Saccharides
|
IN2009KN04098A
(da)
|
2007-06-04 |
2015-08-28 |
Novartis Ag |
|
GB0713880D0
(en)
|
2007-07-17 |
2007-08-29 |
Novartis Ag |
Conjugate purification
|
GB0714963D0
(en)
|
2007-08-01 |
2007-09-12 |
Novartis Ag |
Compositions comprising antigens
|
WO2009038889A1
(en)
|
2007-08-02 |
2009-03-26 |
Children's Hospital And Research Center At Oakland |
Fhbp- and lpxl1-based vesicle vaccines for broad spectrum protection against diseases caused by neisseria meningitidis
|
BR122016015627A2
(pt)
|
2007-10-19 |
2018-10-30 |
Novartis Ag |
kit, composição antigênica liofilizada e método para preparação de uma composição imunogênica
|
RU2475496C2
(ru)
|
2008-02-21 |
2013-02-20 |
Новартис Аг |
МЕНИНГОКОККОВЫЕ ПОЛИПЕПТИДЫ fHBP
|
KR101695800B1
(ko)
|
2008-03-05 |
2017-02-22 |
사노피 파스퇴르 |
항원보강제 함유 백신 조성물의 안정화 방법
|
ES2557282T3
(es)
|
2008-03-10 |
2016-01-25 |
Children's Hospital & Research Center At Oakland |
Proteínas quiméricas de unión al factor H (fHBP) que contienen un dominio B heterólogo, y métodos de uso
|
WO2009143168A2
(en)
|
2008-05-19 |
2009-11-26 |
Novartis Ag |
Vaccine assays
|
CA2726465A1
(en)
|
2008-05-30 |
2009-12-30 |
Wendell David Zollinger |
Meningococcal multivalent native outer membrane vesicle vaccine, methods of making and use thereof
|
EP2326726A4
(en)
|
2008-08-27 |
2011-09-28 |
Childrens Hosp & Res Ct Oak |
FACTOR-BASED H-FACTOR ASSAYS TO DETERMINE BACTERICIDE SERIAL ACTIVITY AGAINST NEISSERIA MENINGITIDIS
|
WO2010028096A2
(en)
|
2008-09-03 |
2010-03-11 |
Children's Hospital & Research Center At Oakland |
Peptides presenting an epitope of an a domain of factor h binding protein and methods of use
|
IT1394288B1
(it)
|
2008-09-12 |
2012-06-06 |
Novartis Vaccines & Diagnostic |
Immunogeni di proteine che legano il fattore h.
|
EP2362767B1
(en)
|
2008-10-29 |
2017-12-06 |
Ablynx N.V. |
Formulations of single domain antigen binding molecules
|
GB0822634D0
(en)
|
2008-12-11 |
2009-01-21 |
Novartis Ag |
Meningitis vaccines
|
JP5410084B2
(ja)
*
|
2008-12-15 |
2014-02-05 |
川上産業株式会社 |
梱包箱及び箱状芯材
|
CA2747340A1
(en)
|
2008-12-17 |
2010-06-24 |
Novartis Ag |
Meningococcal vaccines including hemoglobin receptor
|
CA2756522C
(en)
|
2009-03-24 |
2018-06-26 |
Novartis Ag |
Adjuvanting meningococcal factor h binding protein
|
RU2555757C2
(ru)
|
2009-03-24 |
2015-07-10 |
Новартис Аг |
Комбинации менингококкового фактор н-связывающего белка и пневмококковых сахаридных конъюгатов
|
WO2010127172A2
(en)
|
2009-04-30 |
2010-11-04 |
Children's Hospital & Research Center At Oakland |
Chimeric factor h binding proteins (fhbp) and methods of use
|
US9365885B2
(en)
|
2009-06-16 |
2016-06-14 |
Puiying Annie Mak |
High-throughput complement-mediated antibody-dependent and opsonic bactericidal assays
|
JP2013502918A
(ja)
|
2009-08-27 |
2013-01-31 |
ノバルティス アーゲー |
髄膜炎菌fHBP配列を含むハイブリッドポリペプチド
|
IT1395574B1
(it)
|
2009-09-14 |
2012-10-16 |
Guala Dispensing Spa |
Dispositivo di erogazione
|
CN102724988B
(zh)
|
2009-09-30 |
2014-09-10 |
诺华股份有限公司 |
脑膜炎球菌fHBP多肽的表达
|
GB0917647D0
(en)
|
2009-10-08 |
2009-11-25 |
Glaxosmithkline Biolog Sa |
Expression system
|
JP3158225U
(ja)
*
|
2009-10-22 |
2010-03-25 |
王 文燦 |
折畳める物置袋
|
WO2011051893A1
(en)
|
2009-10-27 |
2011-05-05 |
Novartis Ag |
Modified meningococcal fhbp polypeptides
|
ES2707778T3
(es)
|
2009-12-30 |
2019-04-05 |
Glaxosmithkline Biologicals Sa |
Inmunógenos polisacáridos conjugados con proteínas portadoras de E. coli
|
GB201003922D0
(en)
|
2010-03-09 |
2010-04-21 |
Glaxosmithkline Biolog Sa |
Conjugation process
|
CN102869378A
(zh)
|
2010-03-10 |
2013-01-09 |
葛兰素史密丝克莱恩生物有限公司 |
免疫原性组合物
|
CN102802662A
(zh)
|
2010-03-18 |
2012-11-28 |
诺华有限公司 |
用于脑膜炎球菌血清组b的含佐剂疫苗
|
EP4036104B1
(en)
|
2010-03-30 |
2024-02-21 |
Children's Hospital & Research Center at Oakland |
Factor h binding proteins (fhbp) with altered properties and methods of use thereof
|
WO2011161653A1
(en)
|
2010-06-25 |
2011-12-29 |
Novartis Ag |
Combinations of meningococcal factor h binding proteins
|
PL3246044T5
(pl)
|
2010-08-23 |
2024-06-17 |
Wyeth Llc |
Stabilne preparaty antygenów rLP2086 Neisseria meningitidis
|
WO2012031271A1
(en)
|
2010-09-04 |
2012-03-08 |
Novartis Ag |
Bactericidal antibody assays to assess immunogenicity and potency of meningococcal capsular saccharide vaccines
|
GB201015132D0
(en)
|
2010-09-10 |
2010-10-27 |
Univ Bristol |
Vaccine composition
|
MY166172A
(en)
|
2010-09-10 |
2018-06-07 |
Wyeth Llc |
Non-lipidated variants of neisseria meningitidis orf2086 antigens
|
US20120070457A1
(en)
|
2010-09-10 |
2012-03-22 |
J. Craig Venter Institute, Inc. |
Polypeptides from neisseria meningitidis
|
ES2759484T3
(es)
|
2010-09-10 |
2020-05-11 |
Glaxosmithkline Biologicals Sa |
Meningococo que sobreexpresa NadA y/o NHBA y vesículas de la membrana externa derivadas del mismo
|
GB201101665D0
(en)
|
2011-01-31 |
2011-03-16 |
Novartis Ag |
Immunogenic compositions
|
BR112013022397A2
(pt)
|
2011-03-02 |
2017-09-26 |
Derek OHagan |
vacinas combinadas com doses menores de antígeno e/ou adjuvante
|
US9181308B2
(en)
|
2011-03-28 |
2015-11-10 |
St. Jude Children's Research Hospital |
Methods and compositions employing immunogenic fusion proteins
|
SA115360586B1
(ar)
|
2012-03-09 |
2017-04-12 |
فايزر انك |
تركيبات لعلاج الالتهاب السحائي البكتيري وطرق لتحضيرها
|
NZ628449A
(en)
|
2012-03-09 |
2016-04-29 |
Pfizer |
Neisseria meningitidis compositions and methods thereof
|
ES2685894T3
(es)
|
2013-03-08 |
2018-10-15 |
Pfizer Inc. |
Polipéptidos de fusión inmunogénicos
|
US9965924B2
(en)
|
2013-07-15 |
2018-05-08 |
Ahmnon D. Moskowitz |
Methods, systems, and apparatus for playing multi-zone 21
|
KR101905278B1
(ko)
|
2013-09-08 |
2018-10-08 |
화이자 인코포레이티드 |
나이세리아 메닌지티디스 조성물 및 그의 방법
|
EP3270959A1
(en)
|
2015-02-19 |
2018-01-24 |
Pfizer Inc |
Neisseria meningitidis compositions and methods thereof
|
SG11201906519RA
(en)
|
2017-01-31 |
2019-08-27 |
Pfizer |
Neisseria meningitidis compositions and methods thereof
|